Literature DB >> 6469890

Rifampicin-containing antibiotic combinations in the treatment of difficult infections.

R N Grüneberg, A M Emmerson, G L Ridgway.   

Abstract

Combination of rifampicin with trimethoprim, erythromycin, tetracycline or fusidic acid have some desirable features in the treatment of difficult infections. They are active against a very wide range of possible pathogens. Resistance to rifampicin is rare. Such combinations may be bactericidal and may be usefully synergistic. They may prevent or delay the emergence of bacterial resistant seen when some single agents are used. They can be used in patients with penicillin hypersensitivity. A series of life-threatening infections has been treated with rifampicin-containing combinations. The infections included endocarditis, meningitis, pneumonia, Legionnaire's disease, and head and neck sepsis. A major reason for the choice of drug was often penicillin hypersensitivity. A second reason was the presumption (mostly subsequently confirmed) that streptococci and/or staphylococci were implicated. The clinical outcome of these infections was generally satisfactory, with few side effects and little evidence of the emergence of antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469890     DOI: 10.1093/jac/13.suppl_c.49

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Endophthalmitis as presenting symptom of group G streptococcal endocarditis.

Authors:  P E Verweij; A J Rademakers; P P Koopmans; J F Meis
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

3.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.